61 related articles for article (PubMed ID: 23316969)
1. EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?
Kanwar SS; Nautiyal J; Majumdar AP
Curr Drug Targets; 2010 Jun; 11(6):682-98. PubMed ID: 20298154
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future.
Mulder K; Koski S; Scarfe A; Chu Q; King K; Spratlin J
Oncotarget; 2010 Nov; 1(7):515-529. PubMed ID: 21317448
[TBL] [Abstract][Full Text] [Related]
3. Targeting metastatic upper gastrointestinal adenocarcinomas.
Spratlin JL; Chu Q; Koski S; King K; Mulder K
World J Clin Oncol; 2011 Mar; 2(3):135-49. PubMed ID: 21611088
[TBL] [Abstract][Full Text] [Related]
4. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract][Full Text] [Related]
5. The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis.
Stoup N; Liberelle M; Schulz C; Cavdarli S; Vasseur R; Magnez R; Lahdaoui F; Skrypek N; Peretti F; Frénois F; Thuru X; Melnyk P; Renault N; Jonckheere N; Lebègue N; Van Seuningen I
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830899
[TBL] [Abstract][Full Text] [Related]
6. HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with
Khelwatty SA; Puvanenthiran S; Essapen S; Bagwan I; Seddon AM; Modjtahedi H
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562755
[TBL] [Abstract][Full Text] [Related]
7. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
PLoS One; 2016; 11(2):e0148101. PubMed ID: 26844548
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling.
Huang MJ; Hu RH; Chou CH; Hsu CL; Liu YW; Huang J; Hung JS; Lai IR; Juan HF; Yu SL; Wu YM; Huang MC
Oncotarget; 2015 Mar; 6(8):5650-65. PubMed ID: 25730904
[TBL] [Abstract][Full Text] [Related]
9. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
[TBL] [Abstract][Full Text] [Related]
10. IgE-based Immunotherapy of Cancer -A Comparative Oncology Approach.
Singer J; Jensen-Jarolim E
J Carcinog Mutagen; 2014 May; 5(3):1000176. PubMed ID: 25264496
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic targets for pancreatic cancer.
Tang SC; Chen YC
World J Gastroenterol; 2014 Aug; 20(31):10825-44. PubMed ID: 25152585
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.
Bertino G; Demma S; Ardiri A; Proiti M; Gruttadauria S; Toro A; Malaguarnera G; Bertino N; Malaguarnera M; Malaguarnera M; Di Carlo I
Biomed Res Int; 2014; 2014():203693. PubMed ID: 25089265
[TBL] [Abstract][Full Text] [Related]
13. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.
Li M; Zhang Z; Li X; Ye J; Wu X; Tan Z; Liu C; Shen B; Wang XA; Wu W; Zhou D; Zhang D; Wang T; Liu B; Qu K; Ding Q; Weng H; Ding Q; Mu J; Shu Y; Bao R; Cao Y; Chen P; Liu T; Jiang L; Hu Y; Dong P; Gu J; Lu W; Shi W; Lu J; Gong W; Tang Z; Zhang Y; Wang X; Chin YE; Weng X; Zhang H; Tang W; Zheng Y; He L; Wang H; Liu Y; Liu Y
Nat Genet; 2014 Aug; 46(8):872-6. PubMed ID: 24997986
[TBL] [Abstract][Full Text] [Related]
14. Copy number variation in hereditary non-polyposis colorectal cancer.
Masson AL; Talseth-Palmer BA; Evans TJ; Grice DM; Duesing K; Hannan GN; Scott RJ
Genes (Basel); 2013 Sep; 4(4):536-55. PubMed ID: 24705261
[TBL] [Abstract][Full Text] [Related]
15. Activation of ErbB2 and Downstream Signalling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction.
Akhtar S; Yousif MH; Dhaunsi GS; Sarkhouh F; Chandrasekhar B; Attur S; Benter IF
PLoS One; 2013; 8(6):e67813. PubMed ID: 23826343
[TBL] [Abstract][Full Text] [Related]
16. Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers.
Desai MD; Saroya BS; Lockhart AC
Expert Opin Investig Drugs; 2013 Mar; 22(3):341-56. PubMed ID: 23316969
[TBL] [Abstract][Full Text] [Related]
17. The upgraded role of HER3 and HER4 receptors in breast cancer.
Koutras AK; Fountzilas G; Kalogeras KT; Starakis I; Iconomou G; Kalofonos HP
Crit Rev Oncol Hematol; 2010 May; 74(2):73-8. PubMed ID: 19481955
[TBL] [Abstract][Full Text] [Related]
18. Investigational therapies targeting the ErbB family in oesophagogastric cancer.
Moorcraft SY; Chau I
Expert Opin Investig Drugs; 2014 Oct; 23(10):1349-63. PubMed ID: 24949530
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
